Kaled

Calcifediol, the active ingredient in Kaled, is a vitamin D analog presented as an oral dosage form for oral use. It is used to treat vitamin D deficiency and to support bone health in adults at risk of osteomalacia or osteoporosis. GNH USA supplies Kaled as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kaled, a vitamin D supplementation agent, addresses conditions related to insufficient vitamin D and bone mineralization. - Vitamin D deficiency: restores adequate serum 25‑hydroxyvitamin D levels. - Osteomalacia: improves bone mineralization and reduces bone pain. - Osteoporosis: supports calcium absorption to help maintain bone density.

Calcifediol is generally well tolerated, but some patients may experience adverse reactions.

Common Side Effects: - Hypercalcemia: elevated blood calcium levels. - Hyperphosphatemia: increased phosphate concentrations. - Nausea: mild gastrointestinal discomfort. - Constipation: reduced bowel movements. - Headache: transient head pain.

Serious or Rare Side Effects: - Nephrolithiasis: kidney stone formation. - Cardiac arrhythmia: irregular heart rhythm due to electrolyte imbalance. - Severe hypercalcemia: may cause confusion, muscle weakness, or renal impairment. - Allergic reaction: rash, itching, or swelling. - Pancreatitis: inflammation of the pancreas.

When using Kaled, consider the following safety measures. - Monitor serum calcium and phosphate: regular laboratory testing is advised. - Assess renal function: patients with kidney disease may require dose adjustment. - Evaluate for hyperparathyroidism: excess vitamin D can exacerbate the condition. - Avoid concurrent high‑dose calcium supplements: may increase risk of hypercalcemia. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Calcifediol may interact with several medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Thiazide diuretics: can potentiate hypercalcemia. - Vitamin D analogues (e.g., calcitriol): increase risk of excessive calcium levels. - Lithium: may enhance hypercalcemia risk.

Moderate Interactions (Monitor Closely): - Anticonvulsants (e.g., phenytoin, phenobarbital): may reduce vitamin D levels. - Corticosteroids: can impair vitamin D metabolism. - Orlistat: may decrease absorption of fat‑soluble vitamins.